已收录 268921 条政策
 政策提纲
  • 暂无提纲
Magnesium-L-Aspartate Hydrochloride: Experimental and Clinical Data
[摘要] Epidemiological data suggest that plentiful magnesium (Mg) supply decreases the risk of cardiovascular and other stress-related diseases. Magnesium-L-aspartate hydrochloride (MAH) contains equimolar amounts of Mg and chloride and hence does not affect the equilibrium of non-metabolizable acids and bases. MAH is safe, main pharmacological actions are mediated via Mg-ions and their Ca2+-antagonistic activity. MAH does not bind gastric hydrochloric acid and does not interfere with the enteral absorption of iron, potassium and calcium under physiological conditions, nor with the cytostatic activity of cisplatin and cyclosporine. "Low utilizers" of oral supplements need higher than standard doses (15 mmol) of MAH, individual doses must be increased up to 30-40 mmol. MAH has been proven to attenuate stress reactions in experimental animals, livestock and in humans. Beneficial effects are proven under numerous clinical conditions, eg in obstetrics and gynaecology, in pediatry, cardiology, internal medicine and traumatology. Oral therapy can be optimized by observing plasma/serum and urine Mg levels.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 心脏病和心血管学
[关键词] Kalziumantagonismus;Kinetik;Stressprotektion;Studie;Säuren-Basen-Metabolismus;acid-base metabolism;Ca antagonism;clinical studies;compatibility;kinetics;stress protection [时效性] 
   浏览次数:6      统一登录查看全文      激活码登录查看全文